Portola Pharmaceuticals Announces FDA Accepts NDA for Priority Review for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) accepted Portola ' s New Drug Application (NDA) granting priority review for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news